Home » Stocks » BIOC

Biocept, Inc. (BIOC)

Stock Price: $4.28 USD -0.48 (-10.08%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $4.25 -0.03 (-0.70%) May 13, 7:54 PM
Market Cap 57.36M
Revenue (ttm) 27.46M
Net Income (ttm) -17.81M
Shares Out 11.85M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $4.28
Previous Close $4.76
Change ($) -0.48
Change (%) -10.08%
Day's Open 4.33
Day's Range 4.25 - 4.51
Day's Volume 389,640
52-Week Range 3.46 - 13.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Biocept Inc (NASDAQ:BIOC) (FRA:B003) started 2021 on a high with a profitable first quarter on revenue of $17.8 million, driven primarily by its coronavirus (COVID-19) tests.  For the period ended March...

12 hours ago - Proactive Investors

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #Biocept--Biocept reports profitability for the second consecutive quarter on revenues of $17.8 million for the first quarter of 2021.

1 day ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three months ...

1 week ago - Business Wire

Biocept Inc (NASDAQ:BIOC) has said it is partnering with the Foundation for California Community Colleges to make coronavirus (COVID-19) testing available for the state‘s 116 community colleges and thei...

2 weeks ago - Proactive Investors

SAN DIEGO--(BUSINESS WIRE)--Biocept to provide COVID-19 testing to California community colleges and their more than 2.1 million students through FCCC partnership.

2 weeks ago - Business Wire

Biocept Inc (NASDAQ:BIOC) (FRA:B003) announced the full commercial launch of CNSide, the company's cerebrospinal fluid (CSF) assay designed to better detect and manage the treatment of metastatic cancer...

3 weeks ago - Proactive Investors

SAN DIEGO--(BUSINESS WIRE)-- #cancer--Biocept announces full launch of CNSide, its CSF assay designed to improve the management of metastatic cancers involving the central nervous system.

3 weeks ago - Business Wire

Biocept Inc (NASDAQ:BIOC) (FRA:B003) reports that since the company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples.   These test samples are proce...

4 weeks ago - Proactive Investors

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #Biocept--Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date

4 weeks ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) will host a webinar featuring leading neuro-oncologists to discuss the use of the Company's proprietary cerebrospinal fluid (CSF) assay for diagn...

1 month ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purcha...

1 month ago - Business Wire

Biocept Inc (NASDAQ:BIOC) (FRA:B003) will host a webinar featuring leading neuro-oncologists to discuss the use of its proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that...

1 month ago - Proactive Investors

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will host a webinar featuring leading neuro-oncologists to discuss the...

1 month ago - Business Wire

Biocept Inc (NASDAQ:BIOC) swung to a profit in its fourth-quarter thanks to its coronavirus (COVID-19) testing driving revenue to $18.5 million. For the period ended December 31, 2020, the San Diego-bas...

1 month ago - Proactive Investors

Shares of Biocept (NASDAQ:BIOC) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 170.00% over the past year to $0.14, which beat the ...

1 month ago - Benzinga

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 3...

1 month ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and 12 ...

1 month ago - Business Wire

Patented liquid biopsy technology called Target Selector detects cancer biomarkers Ramping up global marketing efforts for its blood tests and related products to grow organically Has received to date m...

1 month ago - Proactive Investors

Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a $1.8 billion deal on Monday, the same day Veracyte Inc (NASDAQ: VCYT) announced it completed the acquisition of Deciph...

Other stocks mentioned: BMKDF, HTGM
1 month ago - Benzinga

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that President and CEO Michael Nall will participate in thre...

2 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purcha...

2 months ago - Business Wire

Biocept Inc (NASDAQ:BIOC) and privately held life sciences company Aegea Biotechnologies Inc have announced a supply agreement for a new PCR-based coronavirus (COVID-19) assay kit designed by Aegea and ...

2 months ago - Proactive Investors

SAN DIEGO--(BUSINESS WIRE)--Aegea Biotechnologies & Biocept enter supply agreement to validate and commercialize new COVID-19 test to help screen, manage, and evaluate patients.

2 months ago - Business Wire

Biocept Inc (NASDAQ: BIOC) will collaborate with Protean BioDiagnostics Inc to research Biocept's Target Selector molecular assay's ability to determine EGFR status in non-small cell lung cancer (NSCLC)...

2 months ago - Benzinga

Biocept Inc (NASDAQ:BIOC) announced plans Tuesday to collaborate with Protean BioDiagnostics Inc to research the ability of its own Target Selector molecular assays to determine the status of EGFR mutat...

2 months ago - Proactive Investors

SAN DIEGO--(BUSINESS WIRE)--Biocept and Protean BioDiagnostics Collaborate to Demonstrate Advantages of Biocept's Target Selector Assay for Non-Small Cell Lung Cancer Patients.

2 months ago - Business Wire

Biocept Inc (NASDAQ:BIOC) announced Tuesday that its Target Selector molecular assay kit detected mutations in up to 50% of tissue biopsy specimens from non-small cell lung cancer patients that were dee...

2 months ago - Proactive Investors

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay ki...

2 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, provides an update on its...

3 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable in...

3 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, ann...

4 months ago - Business Wire

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically a...

4 months ago - PRNewsWire

SAN DIEGO, Dec. 31, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically ...

4 months ago - PRNewsWire

SAN DIEGO, Dec. 30, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically ...

4 months ago - PRNewsWire

SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically ...

5 months ago - PRNewsWire

Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically ...

6 months ago - PRNewsWire

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an...

6 months ago - PRNewsWire

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically a...

6 months ago - PRNewsWire

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests, products and services designed to provide physicians with clinically ac...

6 months ago - PRNewsWire

SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an...

6 months ago - PRNewsWire

SAN DIEGO, Sept. 4, 2020 /PRNewswire/ -- Biocept, Inc.

8 months ago - PRNewsWire

SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to...

8 months ago - GlobeNewsWire

SAN DIEGO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information ...

8 months ago - GlobeNewsWire

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information...

8 months ago - GlobeNewsWire

Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

SAN DIEGO, Aug. 12, 2020 /PRNewswire/ -- Biocept, Inc.

9 months ago - PRNewsWire

Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.

9 months ago - Zacks Investment Research

About BIOC

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lun... [Read more...]

Industry
Diagnostics & Research
IPO Date
Feb 5, 2014
CEO
Michael Nall
Employees
104
Stock Exchange
NASDAQ
Ticker Symbol
BIOC
Full Company Profile

Financial Performance

In 2020, Biocept's revenue was $27.46 million, an increase of 396.72% compared to the previous year's $5.53 million. Losses were -$17.81 million, -29.16% less than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Biocept stock is "Buy" and the 12-month stock price forecast is 12.00.

Price Target
$12.00
Analyst Consensus: Buy